<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent advances in chemotherapy and <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> have made neoadjuvant treatment an eligible therapeutic option for selected cases of marginally resectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, marginally resectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is not well defined </plain></SENT>
<SENT sid="2" pm="."><plain>The authors suggest that a <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e> is marginally resectable if extended resection such as pelvic exenteration and pancreaticoduedenectomy are not completely curative </plain></SENT>
<SENT sid="3" pm="."><plain>Even if the lesion itself is resectable, it is marginally resectable if it has unfavorable prognostic factors such as numerous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to the regional lymph nodes </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">Rectal cancer</z:e> invading beyond mesorectal fascia, or having bilateral or multiple lateral lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, may also be marginally resectable </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> locally recurrent lesions may be marginally resectable because the prognosis after surgical resection is poor </plain></SENT>
<SENT sid="6" pm="."><plain>Multiple <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> for which resection requires vascular reconstruction, and technically resectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> with unfavorable prognostic factors, are also thought to be marginally resectable </plain></SENT>
<SENT sid="7" pm="."><plain>Neoadjuvant chemotherapy regimens including <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan combined with bevacizumab, cetuximab and panitumumab may be effective for hastening the curability of such marginally resectable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>For primary advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> and locally <z:e sem="disease" ids="C0278554" disease_type="Neoplastic Process" abbrv="">recurrent rectal cancer</z:e>, neoadjuvant radiation combined with chemotherapy using <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan are being explored </plain></SENT>
<SENT sid="9" pm="."><plain>A number of clinical trials are currently ongoing, and are expected to clarify the effectiveness of neoajuvant treatment for marginally resectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>